QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
NASDAQ:XBIO

Xenetic Biosciences (XBIO) Stock Forecast, Price & News

$0.77
-0.01 (-1.28%)
(As of 05/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.72
$0.80
50-Day Range
$0.61
$1.14
52-Week Range
$0.45
$5.68
Volume
49,520 shs
Average Volume
180,785 shs
Market Capitalization
$11.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.53
30 days | 90 days | 365 days | Advanced Chart
Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Xenetic Biosciences logo

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Headlines

Xenetic Biosciences reports Q1 results
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIO
Fax
N/A
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.16 million
Book Value
$1.37 per share

Profitability

Net Income
$-5.64 million
Net Margins
-433.70%
Pretax Margin
-433.70%

Debt

Price-To-Earnings

Miscellaneous

Free Float
13,658,000
Market Cap
$11.02 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
5/18/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

742nd out of 1,426 stocks

Pharmaceutical Preparations Industry

356th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -













Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

Is Xenetic Biosciences a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xenetic Biosciences stock.
View analyst ratings for Xenetic Biosciences
or view top-rated stocks.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 406,900 shares, an increase of 449.1% from the April 15th total of 74,100 shares. Based on an average trading volume of 200,900 shares, the short-interest ratio is currently 2.0 days.
View Xenetic Biosciences' Short Interest
.

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Xenetic Biosciences
.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The company had revenue of $0.35 million for the quarter, compared to analysts' expectations of $0.20 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 36.03% and a negative net margin of 433.70%.
View Xenetic Biosciences' earnings history
.

What price target have analysts set for XBIO?

1 equities research analysts have issued 1-year price targets for Xenetic Biosciences' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Xenetic Biosciences' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 419.5% from the stock's current price.
View analysts' price targets for Xenetic Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Xenetic Biosciences' key executives?
Xenetic Biosciences' management team includes the following people:
  • Mr. Jeffrey F. Eisenberg, CEO & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)
What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.42%) and Simplex Trading LLC (0.00%).

Which institutional investors are selling Xenetic Biosciences stock?

XBIO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Simplex Trading LLC.

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $0.77.

How much money does Xenetic Biosciences make?

Xenetic Biosciences has a market capitalization of $11.02 million and generates $1.16 million in revenue each year.

How many employees does Xenetic Biosciences have?

Xenetic Biosciences employs 4 workers across the globe.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is www.xeneticbio.com.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.